With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4733-39-5,2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.,4733-39-5
(1) Synthesis of 2,9-bis(tosylaminomethyl)-4,7-diphenyl-1,10-phenanthroline (x) 2,9-Bis(aminomethyl)-4,7-diphenyl-1,10-phenanthroline perchlorate (w) (2.36 g, 4 mmol), which was synthesised from 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline according to the method described in J. Heterocyclic Chem., 18, 599 (1981), was dissolved in pyridine (20 ml). p-Toluene sulfonyl chloride (1.6 g, 8 mmol) was added to the solution with cooling using an ice bath, and the reaction mixture was stirred at room temperature for 3 hours. The resulting solution was poured into water (200 ml) and extracted with chloroform (200 ml). The chloroform layer was chromatographed on a silica gel column using chloroform/methanol as eluent to give the desired 2,9-bis(tosylaminomethyl)-4,7-diphenyl-1,10-phenanthroline (x) (yield=1.54 g).
4733-39-5 2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline 65149, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Patent; Dojindo Laboratories; Mochida Pharmaceutical Co., Ltd.; US5262526; (1993); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI